VTRO (Vitro Biopharma) Short-Term Debt: $0.00 Mil (As of Oct. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vitro Biopharma Short-Term Debt?

Vitro Biopharma VTRO Short-Term Debt is $0.00 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's Short-Term Debt for the quarter that ended in Oct. 2022 was $0.00 Mil.

Vitro Biopharma's quarterly Short-Term Debt increased from Oct. 2017 ($0.05 Mil) to Oct. 2021 ($0.06 Mil) but then declined from Oct. 2021 ($0.06 Mil) to Oct. 2022 ($0.00 Mil).

Vitro Biopharma's annual Short-Term Debt increased from Oct. 2017 ($0.05 Mil) to Oct. 2021 ($0.06 Mil) but then declined from Oct. 2021 ($0.06 Mil) to Oct. 2022 ($0.00 Mil).

Vitro Biopharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Vitro Biopharma Short-Term Debt Related Terms

Vitro Biopharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Short-Term Debt Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.04 0.05 0.06 0.00

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.05 0.06 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Vitro Biopharma (VTRO) has a Short-Term Debt of $0.00 Mil as of Oct. 2022.
Is Vitro Biopharma's Short-Term Debt too high?
Vitro Biopharma's current Short-Term Debt is $0.00 Mil.
How does Vitro Biopharma's Short-Term Debt compare to ?
Vitro Biopharma's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Vitro Biopharma's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Short-Term Debt is $0.00 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.